Back to top
more

BioMarin Pharmaceutical (BMRN)

(Delayed Data from NSDQ)

$77.56 USD

77.56
3,399,463

+0.59 (0.77%)

Updated May 17, 2024 04:00 PM ET

After-Market: $77.55 -0.01 (-0.01%) 6:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BMRN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

BioMarin Pharmaceutical Inc. [BMRN]

Reports for Purchase

Showing records 721 - 740 ( 814 total )

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 721

10/04/2012

Company Report

Pages: 8

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 722

09/30/2012

Industry Report

Pages: 20

October and Remaining 2012 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 723

09/26/2012

Company Report

Pages: 8

Pipeline Progress: PEG-PAL Will Continue Into Phase 3 And BMN-111 Will Continue Into Phase 2; PEG-PAL Phase 2 Success Increases Our Fair Value To $39

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 724

09/20/2012

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of September 23

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 725

09/07/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of September 9, 2012

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 726

08/31/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of September 2, 2012

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 727

08/30/2012

Industry Report

Pages: 20

September and Remaining 2012 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 728

08/10/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 729

08/06/2012

Industry Report

Pages: 17

August and Remaining 2012 Catalysts for Emerging Pharmaceuticals.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 730

08/03/2012

Company Report

Pages: 7

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 731

08/02/2012

Company Report

Pages: 9

Q2 Financials: Choppy Naglazyme Revenue & High Operating Expenses Caused A Miss, But We Believe Long- Term Growth Remains Intact.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 732

07/29/2012

Company Report

Pages: 8

Q2 Preview: We Believe Consensus Revenue Estimates Are Achievable

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 733

07/27/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 29

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 734

07/18/2012

Company Report

Pages: 8

Price: 24.95

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 735

07/06/2012

Industry Report

Pages: 17

Emerging Pharmaceuticals - July and Remaining 2012 Catalysts for Emerging Pharmaceuticals

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 736

06/29/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 1

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 737

06/22/2012

Industry Report

Pages: 5

LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of June 24

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 738

06/08/2012

Company Report

Pages: 7

Model Update for Recent Financing Which Extends Cash Runway Well Past Potential Profitability

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 739

06/08/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: BioMarin Pharmaceutical Inc.

Industry: Medical - Biomedical and Genetics

Record: 740

06/03/2012

Industry Report

Pages: 19

Movie Rental and Exhibitor Biweekly Newsletter-May 21 - June 3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 50.00

Research Provided by a Third Party